Drug Name Hoodia

Rimonabant (also known as SR141716; trade names Acomplia, Bethin, Monaslim, Remonabent, Riobant, Slimona, Rimoslim, Zimulti, and Riomont) is an anorectic antiobesity drug. It is an inverse agonist for the cannabinoid receptor CB1. Its main effect is reduction in appetite. Rimonabant was the first selective CB1 receptor blocker to be approved for use anywhere in the world.
Sanofi-aventis announces that concerning the New Drug Application for rimonabant in the United States, the Food and Drug Administration has considered its October 26, 2006 resubmission to be a complete, class 2 response to the FDA February 17, 2006 action letter.

 

A recent study has shown that lithium carbonate and sodium valproate, another drug traditionally used to treat the disorder, act in the brain by inhibiting PKC’s activity and help to create other compounds that also inhibit the PKC. Lithium carbonate is of little use for someone suffering from depression.
Despite a recent recommendation that hemoglobin A1c (HbA1c) be used as a standard diagnostic test for diabetes, the proposed diagnostic criteria fail to pick up a significant number of cases of diabetes and prediabetes, investigators reported at the 70th Annual Scientific Sessions of the American Diabetes Association.